Blue Trust’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
Other funds holding GALT
Blue Trust's GALT Position: Q3 2026 in Review
Blue Trust held its Galectin Therapeutics (GALT) position steady in Q3 2026 at 7,000 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1410.
Blue Trust first reported a position in GALT in Q2 2022 and has held it in 18 quarters since. The position peaked at $32.5K in Q2 2026. 88 funds tracked by Wall St. Rank hold GALT as of Q3 2026.
- Blue Trust held 7,000 shares of Galectin Therapeutics worth $27.2K as of Q3 2026.
- Blue Trust left its Galectin Therapeutics share count unchanged in Q3 2026.
- Galectin Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #1410 holding.
- Blue Trust first reported a position in Galectin Therapeutics in Q2 2022 and has held it in 18 quarters since.
- Blue Trust's Galectin Therapeutics position peaked at $32.5K in Q2 2026.
- 88 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.
Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.